001037247 001__ 1037247
001037247 005__ 20250813203212.0
001037247 0247_ $$2doi$$a10.1093/neuonc/noae082
001037247 0247_ $$2ISSN$$a1522-8517
001037247 0247_ $$2ISSN$$a1523-5866
001037247 0247_ $$2datacite_doi$$a10.34734/FZJ-2025-00580
001037247 0247_ $$2pmid$$a38695575
001037247 0247_ $$2WOS$$aWOS:001269694700001
001037247 037__ $$aFZJ-2025-00580
001037247 082__ $$a610
001037247 1001_ $$0P:(DE-HGF)0$$aWang, Justin Z$$b0
001037247 245__ $$aMeningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
001037247 260__ $$aOxford$$bOxford Univ. Press$$c2024
001037247 3367_ $$2DRIVER$$aarticle
001037247 3367_ $$2DataCite$$aOutput Types/Journal article
001037247 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754987750_30977
001037247 3367_ $$2BibTeX$$aARTICLE
001037247 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001037247 3367_ $$00$$2EndNote$$aJournal Article
001037247 520__ $$aMeningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.Keywords: extra-axial; meningioma; methylation; molecular; neurofibromatosis 2; nonmalignant; radiotherapy.
001037247 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001037247 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001037247 7001_ $$0P:(DE-HGF)0$$aLandry, Alexander P$$b1
001037247 7001_ $$0P:(DE-HGF)0$$aRaleigh, David R$$b2
001037247 7001_ $$00000-0001-5441-1962$$aSahm, Felix$$b3
001037247 7001_ $$00000-0002-5879-9981$$aWalsh, Kyle M$$b4
001037247 7001_ $$0P:(DE-HGF)0$$aGoldbrunner, Roland$$b5
001037247 7001_ $$0P:(DE-HGF)0$$aYefet, Leeor S$$b6
001037247 7001_ $$0P:(DE-HGF)0$$aTonn, Jörg C$$b7
001037247 7001_ $$0P:(DE-HGF)0$$aGui, Chloe$$b8
001037247 7001_ $$0P:(DE-HGF)0$$aOstrom, Quinn T$$b9
001037247 7001_ $$0P:(DE-HGF)0$$aBarnholtz-Sloan, Jill$$b10
001037247 7001_ $$0P:(DE-HGF)0$$aPerry, Arie$$b11
001037247 7001_ $$0P:(DE-HGF)0$$aEllenbogen, Yosef$$b12
001037247 7001_ $$0P:(DE-HGF)0$$aHanemann, C Oliver$$b13
001037247 7001_ $$0P:(DE-HGF)0$$aJungwirth, Gerhard$$b14
001037247 7001_ $$0P:(DE-HGF)0$$aJenkinson, Michael D$$b15
001037247 7001_ $$0P:(DE-HGF)0$$aTabatabai, Ghazaleh$$b16
001037247 7001_ $$0P:(DE-HGF)0$$aMathiesen, Tiit I$$b17
001037247 7001_ $$0P:(DE-HGF)0$$aMcDermott, Michael W$$b18
001037247 7001_ $$0P:(DE-HGF)0$$aTatagiba, Marcos$$b19
001037247 7001_ $$0P:(DE-HGF)0$$ala Fougère, Christian$$b20
001037247 7001_ $$0P:(DE-HGF)0$$aMaas, Sybren L N$$b21
001037247 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b22
001037247 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b23
001037247 7001_ $$0P:(DE-HGF)0$$aBrastianos, Priscilla K$$b24
001037247 7001_ $$0P:(DE-HGF)0$$aEhret, Felix$$b25
001037247 7001_ $$0P:(DE-HGF)0$$aMinniti, Giuseppe$$b26
001037247 7001_ $$0P:(DE-HGF)0$$aLamszus, Katrin$$b27
001037247 7001_ $$0P:(DE-HGF)0$$aRicklefs, Franz L$$b28
001037247 7001_ $$00000-0002-9168-6209$$aSchittenhelm, Jens$$b29
001037247 7001_ $$0P:(DE-HGF)0$$aDrummond, Katharine J$$b30
001037247 7001_ $$0P:(DE-HGF)0$$aDunn, Ian F$$b31
001037247 7001_ $$0P:(DE-HGF)0$$aPathmanaban, Omar N$$b32
001037247 7001_ $$0P:(DE-HGF)0$$aCohen-Gadol, Aaron A$$b33
001037247 7001_ $$0P:(DE-HGF)0$$aSulman, Erik P$$b34
001037247 7001_ $$0P:(DE-HGF)0$$aTabouret, Emeline$$b35
001037247 7001_ $$0P:(DE-HGF)0$$aLe Rhun, Emelie$$b36
001037247 7001_ $$0P:(DE-HGF)0$$aMawrin, Christian$$b37
001037247 7001_ $$0P:(DE-HGF)0$$aMoliterno, Jennifer$$b38
001037247 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b39
001037247 7001_ $$0P:(DE-HGF)0$$aBi, Wenya$$b40
001037247 7001_ $$0P:(DE-HGF)0$$aGao, Andrew$$b41
001037247 7001_ $$0P:(DE-HGF)0$$aYip, Stephen$$b42
001037247 7001_ $$0P:(DE-HGF)0$$aNiyazi, Maximilian$$b43
001037247 7001_ $$00000-0001-5119-7550$$aAldape, Kenneth$$b44
001037247 7001_ $$0P:(DE-HGF)0$$aWen, Patrick Y$$b45
001037247 7001_ $$0P:(DE-HGF)0$$aShort, Susan$$b46
001037247 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b47
001037247 7001_ $$0P:(DE-HGF)0$$aNassiri, Farshad$$b48
001037247 7001_ $$00000-0002-6637-4502$$aZadeh, Gelareh$$b49$$eCorresponding author
001037247 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae082$$gVol. 26, no. 10, p. 1742 - 1780$$n10$$p1742 - 1780$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
001037247 8564_ $$uhttps://juser.fz-juelich.de/record/1037247/files/PDF.pdf$$yOpenAccess
001037247 909CO $$ooai:juser.fz-juelich.de:1037247$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001037247 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b22$$kFZJ
001037247 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001037247 9141_ $$y2024
001037247 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001037247 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001037247 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001037247 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001037247 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001037247 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001037247 920__ $$lyes
001037247 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001037247 980__ $$ajournal
001037247 980__ $$aVDB
001037247 980__ $$aI:(DE-Juel1)INM-3-20090406
001037247 980__ $$aUNRESTRICTED
001037247 9801_ $$aFullTexts